NEW YORK (GenomeWeb) – Protea Biosciences and InSphero today said they will combine their 3D technologies into new products and services to be marketed to the pharmaceutical and biotechnology markets.

The collaboration will use Protea's proprietary LAESI direct molecular imaging platform to analyze InSphero's 3D InSight microtissues, resulting in 3D molecular profiles for tissue characterization, drug metabolism and distribution, pharmacokinetic, and toxicity applications, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.